Skip to main content

Table 3 Rates of patients in whom FPS-R improved or worsened by more than 0.5 units

From: Efficacy and tolerability of α-galactosidase in treating gas-related symptoms in children: a randomized, double-blind, placebo controlled trial

Variable α-galactosidase placebo P
(N = 27) (N = 25)
Pts with difference of FPS-R score < −0.5, n (%) 14 (52%) 8 (32%) 0.15
Pts with difference of FPS-R score > 0.5, n (%) 3 (11%) 6 (24%) 0.22